Surgimatix is a medical device startup pioneering novel, proprietary platform technology that delivers suture-like fixation with a simple squeeze of the handle, cost effectively for surgeons performing minimally invasive procedures.
Technology
Timeline
2017
Received First Patent
To date, 43 active and issued patents and additional applications pending.
2020/2021
Strengthened Clincal and Industry Experience, Obtained FDA 510(k) Clearance
Indication for Use: “The Surgimatix Absorbable Fixation System is indicated for the approximation of soft tissue and fixation of surgical mesh to tissues during open or laparoscopic surgical procedures, such as hernia repair.”
2022
Expanded Team & Executed Development and Commercialization Plan
Hired CEO, VP Operations & Engineering, and Established Board. Engaged Expert Capabilities – Engineering [relevant medical device experience] & Scientific & Clinical Advisory Board. Commenced Series A financing.
2023/2024
Complete Pre-commercialization Activities
Optimize aproxim8™ device for manufacturability and ergonomics. Transfer to contract manufacturer. Controlled human-use release to generate data for case series. Close series A financing.
2024/2025
Launch aproxim8™
In first indication, and pursue regulatory filings for expanded use and partner. Raise next round of financing. Build commercial team. Expand adoption of aproxim8™.
Team
Jane Kiernan
CEO & Interim CFO
Jafar Hasan
Co-Founder
Michael Shoup
VP, Operations & Engineering
William Roff
Financial Planning & Analysis Manager
David Schaller
Director Engineering
Danny Capua
Engineering
Adam Saban
Engineering
John Crombie
Commercialization
Bryan Knodel
Engineering
John Dichiara
Regulatory
Gary Kobylewski
Model Maker & Surgical Technologist
Design Transfer & Manufacturing Team


We are pleased to announce that Surgimatix has selected Paragon Medical of Mansfield, MA as our Contract Manufacturing Partner. Surgimatix recognizes that having the right partner is critical to leveraging our in-house capabilities, quickly and reliably achieving our commercialization goals, and maximizing the company’s overall value. Paragon has a proven track record developing, scaling-up, and manufacturing high-volume, low cost, complex sterile medical devices, and our fully executed development, design verification and manufacturing transfer Agreements align their incentives with the success of Surgmatix and future stratiegic and distribution partners.
-Michael Shoup, VP Operations and Engineering
Surgeon Advisors
Karen Noblett
MD, MAS
Eric Pauli
MD, FACS, FASGE
Chris Schneider
MD, FACS
Business Advisors
Surgimatix has engaged an impressive group of highly experienced, networked medical device leaders with a track record of creating significant value through their business acumen, financial, and operational experience. These individuals are motivated to improve the delivery of healthcare, help early-stage companies succeed, and generate attractive returns.
Join Our Team
Open Positions
Surgeon Advisors [Consultants] are paid by Surgimatix.